[{"orgOrder":0,"company":"Circio","sponsor":"Neoregen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Preclinical","graph3":"Circio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circio \/ Circio","highestDevelopmentStatusID":"4","companyTruncated":"Circio \/ Circio"}]

Find Clinical Drug Pipeline Developments & Deals by Circio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : The collaboration between Circio Holding ASA and NeoRegen Biotech is focused on advancing circular RNA (circRNA) expression-based therapeutics toward clinical readiness.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          June 30, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Preclinical

                          Recipient : Neoregen Biotech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank